Cited 0 times in Scipus Cited Count

Predictive factors of stable or progressive disease during anthracycline with/without taxane-based neoadjuvant chemotherapy in breast cancer

DC Field Value Language
dc.contributor.advisor한, 세환-
dc.contributor.authorJIN, MING-
dc.date.accessioned2016-11-30T23:41:26Z-
dc.date.available2016-11-30T23:41:26Z-
dc.date.issued2016-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/13074-
dc.description.abstractPurpose: Neoadjuvant chemotherapy (NAC) has been shown to effectively downstage locally advanced breast cancer; however, clinically, no response or a progression of the tumor can occur in some cases. Predictive factors of no response or progression are unknown compared to predictive factors of a response. We investigated predictive factors of stable (SD) or progressive disease (PD) during anthracycline with/without taxane based NAC.

Methods: From January 2012 to December 2015, data were collected retrospectively by reviewing medical records of patients who received NAC. Statistical analysis was performed to compare patients with a partial response and complete remission to patients with SD or PD after anthracycline- or taxane-based chemotherapy.

Results: In total, 242 patients received NAC with an anthracycline and cyclophosphamide (AC) regimen and 159 patients received anthracycline followed by taxane. Forty-one (17%) patients had SD or PD after anthracycline treatment, and 50 (31%) patients had SD or PD after taxane treatment. Factors related to SD/PD after an AC regimen included a large pretreatment tumor size (p = 0.001), clinical T3 status (p = 0.01) and high histologic grade (p < 0.001). In cases of a T regimen, clinical T3 status (p = 0.04), estrogen receptor(ER)/progesterone receptor (PR) positivity (p = 0.04, 0.02, respectively), and human epidermal growth factor 2(HER2) negativity (p < 0.001) were predictors of no response.SD or PD after taxane was a negative predictor of disease-free survival. Moreover, SD or PD after anthracycline or taxane was a negative predictor of overall survival.

Conclusions: Clinical stage, ER/PR positivity and HER2 negativity were predictors of no response to NAC. We need a combination of predictive factors including clinical data, novel molecular markers, and genetic factors to identify patients who will show no response to the standard NAC regimen.
-
dc.description.tableofcontentsⅠ. INTRODUCTION 1

Ⅱ. METHODS 2

A. Study population 2

B. Staging and Treatment 2

C. Assessment of tumor response 3

D. Statistical analysis 3

Ⅲ. RESULTS 4

A. Response to anthracycline-based regimen 4

B. Response to taxane-based regimen 5

C. Pathologic response after neoadjuvant chemotherapy 8

D. Predictive factors of no response to neoadjuvant chemotherapy 8

E. Clinical outcomes 10

Ⅳ. DISCUSSION 12

Ⅴ. CONCLUSION 16

REFERENCES 17
-
dc.formattext/plain-
dc.language.isoen-
dc.titlePredictive factors of stable or progressive disease during anthracycline with/without taxane-based neoadjuvant chemotherapy in breast cancer-
dc.title.alternative유방암 환자의 선행항암화학요법 중 유방암의 진행 예측인자에 관한 연구-
dc.typeThesis-
dc.identifier.urlhttp://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000023176-
dc.subject.keywordneoplasms-
dc.subject.keywordNeoadjuvant therapy-
dc.subject.keywordDisease Progression-
dc.description.degreeMaster-
dc.contributor.department대학원 의학과-
dc.contributor.affiliatedAuthorJIN, MING-
dc.date.awarded2016-
dc.type.localTheses-
dc.citation.date2016-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
Appears in Collections:
Theses > School of Medicine / Graduate School of Medicine > Master
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse